La Jolla Buy Hold or Sell Recommendation

LJPC -- USA Stock  

USD 10.40  0.18  1.76%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding La Jolla Pharmaceutical Company is 'Buy'. Macroaxis provides La Jolla buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding La Jolla positions. The advice algorithm takes into account all of La Jolla Pharmaceutical available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from La Jolla buy-and-hold prospective. Please see also La Jolla Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Symbol
Execute Advice
Sell La JollaBuy La Jolla
Buy

Volatility

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

Inapplicable
For the selected time horizon La Jolla Pharmaceutical Company has a risk adjusted performance of 0.1854, jensen alpha of 0.5053, total risk alpha of 0.6267, sortino ratio of 0.2571 and treynor ratio of 2.64
Our buy or sell recommendation tool can be used to cross verify current analyst consensus on La Jolla Pharmaceutical Company and to analyze the entity potential to grow in the coming quarters. To make sure La Jolla Pharmaceutical is not overpriced, please verify all La Jolla Pharmaceutical Company fundamentals including its Shares Owned by Insiders, EBITDA, Short Ratio, as well as the relationship between Price to Book and Total Debt . Given that La Jolla Pharmaceutical has Price to Earning of (6.45)X, we recommend you check La Jolla market performance and probability of bankruptcy to make sure the company can sustain itself in the coming quarters given your latest risk tolerance and investing horizon.

La Jolla Trading Alerts and Improvement Suggestions

La Jolla has high likelihood to experience some financial distress in the next 2 years
The company reported previous year revenue of 17.75M. Net Loss for the year was (158.26M) with loss before overhead, payroll, taxes, and interest of (106.49M).
LA JOLLA PHARMA currently holds about 123.45M in cash with (118.15M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.55.
Over 105.0% of the company shares are owned by institutional investors

La Jolla current analysts recommendations

Target Median Price20.00
Target Mean Price19.80
Recommendation Mean2.20
Target High Price27.00
Number Of Analyst Opinions5
Target Low Price7.00

La Jolla Returns Distribution Density

Mean Return0.51Value At Risk3.2
Potential Upside5.23Standard Deviation2.60
 Return Density 
      Distribution 

Institutional Investors

Security TypeSharesValue
Tang Capital Management LlcCommon Shares4.9 M45.7 M
Fmr LlcCommon Shares4.1 M37.6 M
Rtw Investments LpCommon Shares2 M18.6 M
Sectoral Asset Management IncCommon Shares1.7 M15.3 M
Baker Bros Advisors LpCommon Shares1.6 M14.4 M
Blackrock IncCommon Shares1.4 M13.1 M
Sio Capital Management LlcCommon Shares1.3 M12.1 M

La Jolla Greeks

α
Alpha over DOW
=0.51
β
Beta against DOW=0.19
σ
Overall volatility
=2.61
Ir
Information ratio =0.21

La Jolla Volatility Alert

La Jolla Pharmaceutical Company currently demonstrates below average downside deviation of 2.11. It has Information Ratio of 0.21 and Jensen Alpha of 0.51. However, we do advice investors to further question La Jolla Pharmaceutical Company expected returns to make sure all indicators are consistent with the current outlook about its relatively low value at risk.
    
 Better Than Average     
    
 Worse Than Average Compare La Jolla to competition

La Jolla Fundamental Vs Peers

FundamentalsLa JollaPeer Average
Return On Equity(307.09)% (0.31)%
Return On Asset(40.87)% (0.14)%
Operating Margin(816.09)% (5.51)%
Current Valuation259.26M16.62B
Shares Outstanding27.08M571.82M
Shares Owned by Insiders6.08% 10.09%
Shares Owned by Institutions104.64% 39.21%
Number of Shares Shorted6.14M4.71M
Price to Earning(6.45)X28.72X
Price to Book30.11X9.51X
Price to Sales14.12X11.42X
Revenue17.75M9.43B
Gross Profit(106.49M)27.38B
EBITDA(140.29M)3.9B
Net Income(158.26M)570.98M
Cash and Equivalents123.45M2.7B
Cash per Share4.55X5.01X
Total Debt154.89M5.32B
Current Ratio6.02X2.16X
Book Value Per Share(0.61)X1.93K
Cash Flow from Operations(118.15M)971.22M
Short Ratio11.09X4.00X
Earnings Per Share(5.92)X3.12X
Price to Earnings To Growth(0.15)X4.89X
Number of Employees16918.84K
Beta3.01-0.15
Market Capitalization250.66M19.03B
Total Asset89.52M29.47B
Retained Earnings(438.79M)9.33B
Working Capital79.5M1.48B
Current Asset86.74M9.34B
Current Liabilities7.24M7.9B
Z Score-8.38.72
   Acquisition by Darryl Wellinghoff of 198 shares of La Jolla subject to Rule 16b-3 [view details]

La Jolla Market Momentum

Search macroaxis.com